---
layout: default
title: Ropeginterferon Alfa-2B
parent: Model Prediction Only (L5)
nav_order: 1133
evidence_level: L5
indication_count: 10
---

# Ropeginterferon Alfa-2B
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Ropeginterferon alfa-2b: From Polycythemia Vera to Laubry-Pezzi Syndrome

## One-Sentence Summary

Ropeginterferon alfa-2b is a long-acting (mono-pegylated) interferon alfa-2b marketed in the US as BESREMi. Its approved use is polycythemia vera, taken from the Evidence Pack's rationale text because the license record itself has no indication text.
The TxGNN model predicts it may be effective for **Laubry-Pezzi syndrome** (a ventricular septal defect with aortic regurgitation), but this prediction has **0 clinical trials** and **0 publications** behind it. It is most likely a knowledge-graph artifact.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Polycythemia vera (inferred from the rationale text; the license record's indication text is blank) |
| Predicted New Indication | Laubry-Pezzi syndrome |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 1 (BLA761166) |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available from DrugBank in this record. From the pack's rationale, ropeginterferon alfa-2b is a mono-pegylated interferon alfa-2b that acts as an interferon receptor (IFNAR) agonist. It has antiproliferative and immunomodulatory effects, which is why it is used in a blood cancer such as polycythemia vera.

Laubry-Pezzi syndrome is a structural heart defect: a ventricular septal defect with aortic regurgitation. It is not a proliferative, inflammatory or interferon-responsive process. **No plausible mechanistic link was identified.**

The score of 0.999 most likely reflects graph proximity among rare-disease nodes rather than real biology. The other nine top-ranked predictions have the same problem. They are cardiac malformations, craniofacial syndromes and chromosomal deletion disorders, and none has trial or literature support.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## US Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| BLA 761166 | BESREMi (PharmaEssentia USA) | Injection | Not listed in the record |

## Safety Considerations

Please refer to the package insert for safety information. No drug-drug interaction records were found for this drug.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction has no clinical trials, no literature and no plausible mechanism, so it stays at evidence level L5. The 99.93% TxGNN score alone is not enough to justify further investment. Interferon-alpha has no known role in a structural cardiac defect.

**To proceed, the following is needed:**
- A biological rationale linking interferon-alpha signaling to Laubry-Pezzi syndrome, or a decision to drop this prediction
- The US package insert (warnings and contraindications) for safety screening
- Mechanism of action data from DrugBank
- The approved indication text for BLA761166
- A route-compatibility assessment, which is still pending
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

